신경아교세포와 조현병 = Neuroglial Cells and Schizophrenia

다국어 초록 (Multilingual Abstract)

In the past decade, structural, molecular, and functional changes in glial cells have become a major focus in the search for the neurobiological foundations of schizophrenia. Glial cells, consisting of oligodendrocytes, astrocytes, microglia, and nerve/glial antigen 2-positive cells, constitute a major cell population in the central nervous system. There is accumulating evidence of reduced numbers of oligodendrocytes and altered expression of myelin/oligodendrocyte-related genes that might explain the white matter abnormalities and altered inter- and intra-hemispheric connectivities that are characteristic signs of schizophrenia. Astrocytes play a key role in the synaptic metabolism of neurotransmitters ; thus, astrocyte dysfunction may contribute to certain aspects of altered neurotransmission in schizophrenia. Increased densities of microglial cells and aberrant expression of microglia-related surface markers in schizophrenia suggest that immunological/inflammatory factors are of considerable relevance to the pathophysiology of psychosis. This review describes current evidence for the multifaceted role of glial cells in schizophrenia and discusses efforts to develop glia-directed therapies for the treatment of the disease.

참고문헌 (Reference)

1 Dwork AJ, "White matter and cognitive function in schizophrenia" 10 : 513-536, 2007

2 Kolomeets NS, "Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postortem morphometric study" 11 (11): 282-292, 2010

3 Uranova NA, "The role of oligodendrocyte pathology in schizophrenia" 10 : 537-545, 2007

4 Amar S, "The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases" 17 : 2264-2277, 2011

5 Cannon DM, "The association of white matter volume in psychotic disorders with genotypic variation in NRG1, MOG and CNP: a voxel-based analysis in affected individuals and their unaffected relatives" 2 : e167-, 2012

6 Roussos P, "The association of schizophrenia risk D-amino acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males" 36 : 1677-1688, 2011

7 Rosenbluth J, "Structural bases for central nervous system malfunction in the quaking mouse: dysmyelination in a potential model of schizophrenia" 91 : 374-381, 2013

8 Labrie V, "Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model" 18 : 3227-3243, 2009

9 Schnieder TP, "Searching for neuropathology: gliosis in schizophrenia" 69 : 134-139, 2011

10 Muller N, "Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission" 10 : 131-148, 2006

11 Bruton CJ, "Schizophrenia and the brain: a prospective clinico-neuropathological study" 20 : 285-304, 1990

12 Rubinov M, "Schizophrenia and abnormal brain network hubs" 15 : 339-349, 2013

13 Takahashi N, "Roles of glial cells in schizophrenia: possible targets for therapeutic approaches" 53 : 49-60, 2013

14 Hertz L, "Receptor expression in primary cultures of neurons or astrocytes" 8 : 521-527, 1984

15 Martins-de-Souza D, "Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia" 43 : 978-986, 2009

16 Abazyan B, "Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology" 68 : 1172-1181, 2010

17 Wan C, "Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population" 388 : 126-131, 2005

18 Qu M, "Polymorphisms of Transferrin gene are associated with schizophrenia in Chinese Han population" 42 : 877-883, 2008

19 Nishiyama A, "Polydendrocytes (NG2cells): multifunctional cells with lineage plasticity" 10 : 9-22, 2009

20 Erhardt S, "Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders" 23 : 91-101, 2009

21 Schmandke A, "Nogo-A: Multiple Roles in CNS Development, Maintenance, and Disease" 20 : 372-386, 2014

22 Novak G, "Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3'-UTR" 1120 : 161-171, 2006

23 Falkai P, "No evidence for astrogliosis in brains of schizophrenic patients. A postmortem study" 25 : 48-53, 1999

24 Stevens JR, "Neuropathology of schizophrenia" 39 : 1131-1139, 1982

25 Uranova NA, "Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses" (7) : 42-48, 2001

26 Chaudhry IB, "Minocycline benefits negative symptoms in early schizophrenia:a randomised double-blind placebo-controlled clinical trial in patients on standard treatment" 26 : 1185-1193, 2012

27 van Berckel BN, "Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study" 64 : 820-822, 2008

28 Miller BJ, "Metaanalysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects" 70 : 663-671, 2011

29 Bernstein HG, "Lysosomal proteinases as putative diagnostic tools in human neuropathology: Alzheimer disease (AD) and schizophrenia" 42 : 19-24, 1992

30 Hof PR, "Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia" 53 : 1075-1085, 2003

31 Rajkowska G, "Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia" 57 : 127-138, 2002

32 Haroutunian V, "Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia" 10 : 499-502, 2007

33 Matute C, "Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics" 49 : 451-455, 2005

34 Lai AY, "Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines" 53 : 809-816, 2006

35 Kondziella D, "How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?" 50 : 291-301, 2007

36 Bernstein HG, "Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy" 161 : 4-18, 2015

37 Zai G, "Genetic study of the myelin oligodendrocyte glycoprotein (MOG) gene in schizophrenia" 4 : 2-9, 2005

38 Gutiérrez-Fernández A, "Expression of oligodendrocyte and myelin genes is not altered in peripheral blood cells of patients with first-episode schizophrenia and bipolar disorder" 12 : 107-109, 2010

39 Kubicki M, "Evidence for white matter abnormalities in schizophrenia" 18 : 121-134, 2005

40 Oĭfa AI, "Electron-microscopic analysis of cytoarchitectonic disorders in the cerebral cortex in schizophrenia" 91 : 48-52, 1991

41 Konopaske GT, "Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys" 63 : 759-765, 2008

42 Wonodi I, "Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes" 68 : 665-674, 2011

43 Konrad A, "Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon?" 34 : 72-92, 2008

44 Steiner J, "Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization" 112 : 305-316, 2006

45 Hempel KJ, "Die Gliazelldichte bei klinisch Gesunden und Schizophrenen" 4 : 371-411, 1959

46 Vostrikov VM, "Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders" 94 : 273-280, 2007

47 Vostrikov V, "Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia" 9 : 34-42, 2008

48 Hashimoto K, "Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia" 60 : 572-576, 2003

49 Steffek AE, "Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia" 103 : 71-82, 2008

50 Tanahashi S, "Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes" 165 : 1543-1555, 2012

51 Kalkman HO, "Circumstantial evidence for a role of glutamine-synthetase in suicide" 76 : 905-907, 2011

52 Graeber MB, "Changing face of microglia" 330 : 783-788, 2010

53 Rapaport MH, "Celecoxib augmentation of continuously ill patients with schizophrenia" 57 : 1594-1596, 2005

54 Akhondzadeh S, "Celecoxib as adjunctive therapy in schizophrenia:a double-blind, randomized and placebo-controlled trial" 90 : 179-185, 2007

55 Cohen-Cory S, "Brain-derived neurotrophic factor and the development of structural neuronal connectivity" 70 : 271-288, 2010

56 Müller N, "Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia" 159 : 1029-1034, 2002

57 Powell SB, "Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia" 62 : 1322-1331, 2012

58 Merenlender-Wagner A, "Autophagy has a key role in the pathophysiology of schizophrenia" 20 : 126-132, 2015

59 Benros ME, "Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study" 168 : 1303-1310, 2011

60 Allaman I, "Astrocyte-neuron metabolic relationships: for better and for worse" 34 : 76-87, 2011

61 Williams MR, "Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia" 263 : 41-52, 2013

62 Torrey EF, "Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis" 33 : 729-736, 2007

63 Stroman PW, "Advanced MR imaging techniques and characterization of residual anatomy" 114 : 460-470, 2012

64 Mednick SA, "Adult schizophrenia following prenatal exposure to an influenza epidemic" 45 : 189-192, 1988

65 Voineskos AN, "A family-based association study of the myelin-associated glycoprotein and 2’,3’-cyclic nucleotide 3’-phosphodiesterase genes with schizophrenia" 18 : 143-146, 2008

66 Levkovitz Y, "A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia" 71 : 138-149, 2010

67 Bendikov I, "A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia" 90 : 41-51, 2007